ClinicalTrials.gg
TerminatedNCT01366729Updated Dec 29, 2022

Gait Rehabilitation Post Stroke:the Long Term Effect of Two Walking Aids -Canes and TheraTogs

An interventional study of TheraTogs and Cane walking in Stroke Gait Rehabilitation, sponsored by Technical University of Bern. Terminated at 3 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-29.

Sponsored by Technical University of Bern · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Unable to recruite enough subjects to reach statistical power

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background 9000 people a year in Switzerland suffer a first time stroke. Of these 20 to 30% remain unable to walk and up to 60% are left with moderate to severe walking disability.

Evidence shows that rehabilitation techniques which emphasise use of the hemiplegic side influence ipsilesional cortical plasticity and improve functional outcomes. Canes are commonly used in gait rehabilitation although they significantly reduce hemiplegic muscle activity. We have shown that an orthosis "TheraTogs" ( elastic corset supporting hemiplegic side) significantly increases hemiplegic muscle activity during gait.

To date no clinical studies have investigated the long term effects of these techniques on gait recovery following stroke.

This study aims to determine if advances in the understanding of cortical plasticity and its relation to functional recovery following stroke can be applied to clinical gait rehabilitation to improve long term outcomes.

Hypotheses Early gait rehabilitation with canes will reduce hemiplegic muscle activity and inhibit balance reactions. In the long term this causes poorer walking ability and balance and consequently reduced social participation.

Early gait rehabilitation with TheraTogs will increase hemiplegic muscle activity and facilitate balance reactions. In the long term this improves walking ability and balance leading to increased social independence and participation.

Design Multi-centred, single blind, randomized control trial. Subjects 120 first time stroke patients Intervention When subjects can walk unaided on even ground whilst requiring verbal prompts and stand-by help without body contact (FAC 3) they will be randomly allocated into intervention (TheraTogs) or control (cane) group. TheraTogs will be applied to support hip extensor and abductor musculature according to a standardized procedure. Cane walking with cane at the level of the radial styloid of the sound wrist. Subjects will walk throughout the day with the assigned walking aid. Standard therapy treatments and usual care will remain unchanged and documented.The intervention will continue for five weeks or until patients have reached FAC 5 (independent walkers on all surfaces).

Measures: the day before intervention begin, the day after intervention completion (max 5 weeks), 3 months, 6 months and 2 years after completion Primary outcome Timed "up and go" test Secondary outcomes surface EMG of hemiplegic lower extremity musculature, temporo-spatial gait parameters, hip kinematics, dynamic balance. The Stroke Impact Scale.

Results Significance levels will be 5% with 95% CI's. ITT analyses will be performed. Descriptive statistics will be presented. Relevant co-variables will be identified and analysed. Discussion This study could have significant implications for the clinical practice of gait rehabilitation after stroke in particular the effect and appropriate use of walking aids

02

Conditions studied

  • Stroke Gait Rehabilitation

Browse trials for

Keywords

  • hemiplegia
  • walking
  • canes
  • TheraTogs
  • EMG
  • balance
  • Timed up and go
03

In context

Hemiplegia

450 studies on the registry are indexed under Hemiplegia; 92 are open to participants now.

This study's enrollment of 12 is below the median of 34 across 373 interventional studies indexed under Hemiplegia.

Browse Hemiplegia studies →

Lead sponsor

Technical University of Bern is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with hemiplegia following a first unilateral stroke
  • will score at least level 3 on the Functional Ambulation Category (FAC) (able to walk unaided on even ground but requiring verbal prompts and stand-by help without body contact)
  • must have been independent walkers prior to insult without walking aids
  • Subjects will have a Mini Mental State score of 22 or above

Exclusion criteria

Exclusion Criteria:

  • orthopaedic or other neurological conditions that could limit walking ability
  • no gross visuospatial or visual field deficits
  • no medical to walking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    TheraTogs

    Device: TheraTogs

  • Active comparator
    Cane walking

    Device: Cane walking

Interventions

  • DeviceTheraTogs

    Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.

  • DeviceCane walking

    All walking activities must take place with cane from waking until sleeping

06

What researchers measure

Primary outcomes

  1. Timed "up and go" test

    Time frame: the day after intervention completion (max 5 weeks)

Secondary outcomes

  1. surface EMG of hemiplegic lower extremity musculature

    peak surface EMG of gluteus maximus and medius

    Time frame: the day after intervention completion (max 5 weeks)

  2. temporo-spatial gait parameters

    Time frame: the day after intervention completion (max 5 weeks)

  3. hip kinematics

    hemiplegic hip kinematic measurements in sagital and frontal planes

    Time frame: the day after intervention completion (max 5 weeks)

  4. Dynamic balance

    Sway Star

    Time frame: the day after intervention completion (max 5 weeks)

  5. The Stroke Impact Scale

    Time frame: the day after intervention completion (max 5 weeks)

  6. EMG activation patterns of hemiplegic leg musculature

    EMG activation patterns of gluteus maximus, medius, vastus lateralis, semitendinosis, gastrocnemius and tibialis anterior

    Time frame: 1 day post intervention completion (max 5 weeks)

  7. Accelerometer Activity Monitoring

    The accelerometer (Aipermon® GmbH, Germany) will be attached to the patient's belt and positioned above the left hip. Patients will wear the device during waking hours during intervention time. The accelerometer will be attached after dressing in the morning and only taken off for showering, bathing and sleeping. In the statistical analysis a day starts at 24.00 o'clock and ends at 23.59 o'clock the same day. Mean activity per day will be calculated

    Time frame: Immediately post intervention

07

Study locations

3 sites
  • RehaClinic Bad Zurzach
    Zurzach, Aargau, Switzerland
  • Felix Platterspital
    Basel, Basel-Stadt 4012, Switzerland
  • Kantonsspital Luzern
    Luzern, Switzerland
08

References and documents

Publications

  • Maguire C, Sieben JM, Erzer F, Goepfert B, Frank M, Ferber G, Jehn M, Schmidt-Trucksass A, de Bie RA. How to improve walking, balance and social participation following stroke: a comparison of the long term effects of two walking aids--canes and an orthosis TheraTogs--on the recovery of gait following acute stroke. A study protocol for a multi-centre, single blind, randomised control trial. BMC Neurol. 2012 Mar 30;12:18. doi: 10.1186/1471-2377-12-18. PubMed 22462692 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2011
First posted
Jun 6, 2011
Start
Nov 2011
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Dec 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01366729
Lead sponsor
Technical University of Bern
Collaborators
Maastricht University
Responsible party
Clare Maguire (Principal researcher, Technical University of Bern) — Principal investigator
First posted
Jun 6, 2011
Start date
Nov 2011
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Dec 29, 2022

Study contacts

Clare C Maguire, MSc PT
principal investigator · Technical University of Bern, Bildungszentrun Gesundheit, Basel-Stadt

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion